APhA Annual Meeting & Exposition

“Every pharmacist raises their hand and takes an oath before they graduate to put patients first,” said Bruce Berger, PhD, FAPhA. “But what happens when you exist in an environment every single day where that’s impossible?”

According to Anita Jacobson, PharmD, pharmacists should actively facilitate access to harm reduction programs by providing information and resources, ensuring the person who uses drugs doesn’t have to navigate the landscape on their own.

It’s important that pharmacists continuously revise their counseling as new information about substances such as xylazine, levamisole, and phenacetin emerges, said Anita Jacobson at this year’s American Pharmacists Association Annual Meeting & Exposition.

At APhA 2024, 2 posters looked into how collaboration between physicians and community pharmacists is crucial when it comes to opioid prescriptions, and current opioid use patterns among older adults.

Two posters presented at APhA 2024 examined how the COVID-19 pandemic impacted pharmacists and their work.

Researchers detailed the FDA’s recommendations on low-dose aspirin and pharmacists’ role in cardiovascular practice transformation programs.

Posters presented at the APhA 2024 Annual Meeting and Exposition discussed pharmacist barriers in pediatric immunizations, a novel meningococcal vaccine, and the need for inpatient reviews of vaccination history.

In a poster presented at the 2024 American Pharmacists Association Annual Meeting and Exposition, researchers addressed continuous glucose monitoring and its potential role in indigent communities.

According to Sa’ed Al-Olimat, education and advocacy are key to ensure a safe and accessible landscape of psychedelic therapeutics, especially as the compounds inch closer to the mainstream health care market.

In a poster presented at the 2024 American Pharmacists Association Annual Meeting and Exposition, researchers assessed state-level regulations for PBMs.

Researchers presented their findings on hypersensitivity caused by antibiotics as well as the best ways pharmacists can test for it.

In a conversation at this year’s American Pharmacists Association Annual Meeting & Exposition, Sa’ed Al-Olimat outlined the potential of psychedelic therapeutics in treating mental health disorders.

At this year’s American Pharmacists Association Annual Meeting & Exposition, Mark Garofoli urged pharmacists to develop strong documentation practices and go beyond baseline federal regulations to care for patients with red flags.

Pharmacists must uphold their “corresponding responsibility” to address controlled substance concerns among patients while balancing safety and respect, said Mark Garofoli at this year’s American Pharmacists Association Annual Meeting & Exposition.

The average US household spent $645 on OTC products in 2022.

Adults aged 65 years and older are the largest group of consumers of OTC medications.

The first nonprescription, OTC naloxone nasal spray (Narcan) was approved by the FDA in March 2023.

Medication therapy management can also increase the likelihood of using statins in this population.

Four posters presented at this year’s American Pharmacists Association Annual Meeting & Exposition assessed the potential impact of pharmacist interventions on improving mental health outcomes.

According to posters presented at the 2024 American Pharmacists Association Annual Meeting and Exposition, pharmacists wish to play a bigger role in educating young people about the risks of vaping.

Access to counseling and education were strong predictors of being dispensed contraceptives.

Results from a meta-analysis on the side of effects of the psychedelic psilocybin were presented at the 2024 American Pharmacists Association Annual Meeting & Exposition.

Four posters presented at the American Pharmacists Association Annual Meeting and Exposition explored how individuals and health care providers have been handling the COVID-19 pandemic.

APhA 2024 will take place March 22 to March 25 in Orlando, Florida.

Pharmacists can provide support and guidance to patients during their month of fasting.

Two posters presented at APhA in Phoenix examined the efficacy of the Omnipod® 5 Automated Insulin Delivery System.

COVID-19 misinformation is common. A study presented at the annual APhA meeting examined how new pharmacy practitioners responded to misinformation and tried to minimize its spread.

Are pharmacists obligated to correct medical misinformation they encounter online?

From variants to vaccines, much has changed in the COVID-19 landscape.

Pharmacogenetic testing and therapeutic drug monitoring are feasible in the inpatient psychiatric treatment setting.